← Leaderboards
Peter S Klein
University Of Pennsylvania
$17,059,335
Attributed
$22,809,281
Total exposure
19
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,809,281 · 19
By mechanism
R01$16,903,452 · 9
R21$1,779,972 · 4
R24$1,679,994 · 1
R38$1,406,553 · 1
R56$490,971 · 2
T32$353,535 · 1
Top collaborators
- Wei Tong4 shared
- Sameer Varma4 shared
- Stella T Chou3 shared
- Chyke Abadama Doubeni2 shared
- Jian Huang2 shared
- Zhe Zhang2 shared
- Jaclyn A Biegel1 shared
- Lawrence F Brass1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Jonathan P Katz$21,399,724
- Douglas J Epstein$22,307,735
- Mortimer Poncz$48,626,684
- William F Degrado$44,950,833
- Charles P Emerson$35,198,488
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsIn VivoGlycogen Synthase Kinase 3Novel StrategiesLithiumCellsResponseSignal TransductionMediatingGeneticInsightPlaySignal PathwayRegulationLeadFutureLoss Of FunctionMutationAdultHematopoieticProteinsGenesInhibitor/AntagonistComplex
Grant awards (61)
Mitochondrial dysfunction driven by splicing factor mutations in MDS$3,227,502
R01 · FY2025 · DK · contact PI
Hematology Clinical Research Training Program$353,535
T32 · FY2025 · HL
Molecular mechanisms of lithium action on kinases$315,575
R01 · FY2025 · GM
Professional Development$147,265
U2C · FY2025 · DK · contact PI
Expand human umbilical cord blood hematopoietic stem cells with PPAR-a agonists$127,501
R21 · FY2025 · HL
Molecular mechanisms of lithium action on kinases$315,575
R01 · FY2024 · GM
Expand human umbilical cord blood hematopoietic stem cells with PPAR-a agonists$146,876
R21 · FY2024 · HL
Professional Development$47,539
U2C · FY2024 · DK · contact PI
Molecular mechanisms of lithium action on kinases$315,575
R01 · FY2023 · GM
Molecular mechanisms of lithium action on kinases$325,071
R01 · FY2022 · GM
Targeting splicing in myelodysplasia through GSK-3$99,999
R56 · FY2022 · DK · contact PI
Maintenance and expansion of long-term hematopoietic stem cells$540,335
R01 · FY2021 · HL · contact PI
Targeting Coronavirus through Nucleocapsid Phosphorylation$446,875
R21 · FY2021 · AI · contact PI
The Penn-StARR Program for Research in Residency$349,368
R38 · FY2021 · HL · contact PI
Maintenance and expansion of long-term hematopoietic stem cells$540,336
R01 · FY2020 · HL · contact PI
The Penn-StARR Program for Research in Residency$349,368
R38 · FY2020 · HL · contact PI
Maintenance and expansion of long-term hematopoietic stem cells$540,335
R01 · FY2019 · HL · contact PI
The Penn-StARR Program for Research in Residency$352,039
R38 · FY2019 · HL · contact PI
An unexpected signaling output for the tumor suppressor APC$313,950
R01 · FY2019 · GM · contact PI
Maintenance and expansion of long-term hematopoietic stem cells$540,335
R01 · FY2018 · HL · contact PI
The Penn-StARR Program for Research in Residency$355,778
R38 · FY2018 · HL · contact PI
An unexpected signaling output for the tumor suppressor APC$313,950
R01 · FY2018 · GM · contact PI
Regulation of Neurogenesis and Behavior by GSK-3$463,198
R01 · FY2017 · MH · contact PI
An unexpected signaling output for the tumor suppressor APC$313,950
R01 · FY2017 · GM · contact PI
An unexpected signaling output for the tumor suppressor APC$82,870
R01 · FY2017 · GM · contact PI
Towards Precision Medicine in Childhood Acquired Aplastic Anemia$559,998
R24 · FY2016 · DK
Regulation of Neurogenesis and Behavior by GSK-3$457,610
R01 · FY2016 · MH · contact PI
An unexpected signaling output for the tumor suppressor APC$313,950
R01 · FY2016 · GM · contact PI
Towards Precision Medicine in Childhood Acquired Aplastic Anemia$559,998
R24 · FY2015 · DK
Regulation of Neurogenesis and Behavior by GSK-3$452,109
R01 · FY2015 · MH · contact PI
Towards Precision Medicine in Childhood Acquired Aplastic Anemia$559,998
R24 · FY2014 · DK
Regulation of Neurogenesis and Behavior by GSK-3$520,566
R01 · FY2014 · MH · contact PI
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3$513,041
R01 · FY2014 · HL · contact PI
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3$502,264
R01 · FY2013 · HL · contact PI
Regulation of neurogenesis and behavior by GSK-3$390,972
R56 · FY2013 · MH · contact PI
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3$523,595
R01 · FY2012 · HL · contact PI
Targeting Wnt and mTOR to expand hematopoietic stem cells$200,000
R21 · FY2012 · HL · contact PI
Regulating Hematopoietic Stem Cell Homeostasis through GSK-3$542,962
R01 · FY2011 · HL · contact PI
Targeting Wnt and mTOR to expand hematopoietic stem cells$240,000
R21 · FY2011 · HL · contact PI
A molecular mechanism for lithium action$323,951
R01 · FY2010 · MH · contact PI
A molecular mechanism for lithium action$323,951
R01 · FY2009 · MH · contact PI
Early activation of the zygotic genome$290,572
R01 · FY2009 · GM · contact PI
A molecular mechanism for lithium action$323,951
R01 · FY2008 · MH · contact PI
Early activation of the zygotic genome$290,572
R01 · FY2008 · GM · contact PI
A molecular mechanism for lithium action$323,951
R01 · FY2007 · MH · contact PI
Early activation of the zygotic genome$290,572
R01 · FY2007 · GM · contact PI
A molecular mechanism for lithium action$333,625
R01 · FY2006 · MH · contact PI
Phase II trial of valproic acid in myelodysplasia$305,682
R21 · FY2006 · CA · contact PI
Early activation of the zygotic genome$298,459
R01 · FY2006 · GM · contact PI
A Novel Molecular Target of Valproic Acid$193,470
R01 · FY2006 · MH · contact PI
A Molecular Mechanism for Lithium Action$330,650
R01 · FY2005 · MH
Phase II trial of valproic acid in myelodysplasia$313,038
R21 · FY2005 · CA
A Novel Molecular Target of Valproic Acid$198,125
R01 · FY2005 · MH
A Novel Molecular Target of Valproic Acid$198,125
R01 · FY2004 · MH
A Molecular Mechanism for Lithium Action$141,960
R01 · FY2004 · MH
A Novel Molecular Target of Valproic Acid$198,125
R01 · FY2003 · MH
A Molecular Mechanism for Lithium Action$182,066
R01 · FY2003 · MH
A Novel Molecular Target of Valproic Acid$198,125
R01 · FY2002 · MH
A Molecular Mechanism for Lithium Action$182,534
R01 · FY2002 · MH
A Molecular Mechanism for Lithium Action$182,988
R01 · FY2001 · MH
MOLECULAR MECHANISM FOR LITHIUM ACTION$123,026
R01 · FY2000 · MH